Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Insulin Glargine U 300

Brand: Toujeo®
NICE TA: 
Indication: Type 2 diabetes mellitus
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin glargine 300 units/mL (Toujeo®) is recommended as an option in adults with type 2 diabetes mellitus (T2DM) only in accordance with the recommendations in NICE NG28 and in those who suffer from symptomatic nocturnal hypoglycaemia whilst being treated with a first-line long-acting insulin analogue.
The LMMG recommends Toujeo SoloStar® as the 1st line high strength long-acting insulin analogue.

Recommendation

LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

LMMG New Medicine Assessment - Insulin Glargine U300 T2DM (435.5 KiB)

Insulin Toujeo Information Sheet And Good Practice Guide (Version 1.1) (255.8 KiB)

Algorithm For Antihyperglycaemic Therapy In Adults With Type II V1.5 (467.6 KiB)

 

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Amber0

Amber

Amber0

Amber0

Amber0

Amber0